Molecular Medicine Program.
Department of Neurology.
J Clin Invest. 2022 May 16;132(10). doi: 10.1172/JCI154225.
Ischemic stroke prompts a strong inflammatory response, which is associated with exacerbated outcomes. In this study, we investigated mechanistic regulators of neutrophil extracellular trap (NET) formation in stroke and whether they contribute to stroke outcomes. NET-forming neutrophils were found throughout brain tissue of ischemic stroke patients, and elevated plasma NET biomarkers correlated with worse stroke outcomes. Additionally, we observed increased plasma and platelet surface-expressed high-mobility group box 1 (HMGB1) in stroke patients. Mechanistically, platelets were identified as the critical source of HMGB1 that caused NETs in the acute phase of stroke. Depletion of platelets or platelet-specific knockout of HMGB1 significantly reduced plasma HMGB1 and NET levels after stroke, and greatly improved stroke outcomes. We subsequently investigated the therapeutic potential of neonatal NET-inhibitory factor (nNIF) in stroke. Mice treated with nNIF had smaller brain infarcts, improved long-term neurological and motor function, and enhanced survival after stroke. nNIF specifically blocked NET formation without affecting neutrophil recruitment after stroke. Importantly, nNIF also improved stroke outcomes in diabetic and aged mice and was still effective when given 1 hour after stroke onset. These results support a pathological role for NETs in ischemic stroke and warrant further investigation of nNIF for stroke therapy.
缺血性脑卒中引发强烈的炎症反应,进而导致病情恶化。本研究旨在探究脑卒中中性粒细胞胞外诱捕网(NET)形成的机制调节因子,以及这些调节因子是否与脑卒中结局相关。我们发现,缺血性脑卒中患者的脑组织中存在大量形成 NET 的中性粒细胞,且升高的血浆 NET 生物标志物与较差的脑卒中结局相关。此外,我们还观察到脑卒中患者的血浆和血小板表面高迁移率族蛋白 B1(HMGB1)表达增加。机制研究表明,血小板是 HMGB1 的关键来源,HMGB1 在脑卒中的急性期引起 NET 的形成。脑卒中后,血小板耗竭或血小板特异性敲除 HMGB1 可显著降低血浆 HMGB1 和 NET 水平,极大地改善脑卒中结局。随后,我们研究了新生儿 NET 抑制因子(nNIF)在脑卒中治疗中的潜力。nNIF 治疗的小鼠脑梗死体积较小,长期神经和运动功能改善,脑卒中后存活率提高。nNIF 特异性地阻断 NET 形成,而不影响脑卒中后中性粒细胞的募集。重要的是,nNIF 还可改善糖尿病和老年小鼠的脑卒中结局,并且在脑卒中发病后 1 小时给药仍有效。这些结果支持 NET 在缺血性脑卒中中的病理性作用,并为 nNIF 治疗脑卒中提供了进一步的研究依据。